trial

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia

NCTId NCT01292577
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 33 (actual)
Sponsored by University of Pittsburgh Medical Center
Primary completion 2014-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2010-09
Primary completion
2014-05
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
CET/PT

Sponsors

University of Pittsburgh Medical CenterLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator

Investigators

1
Shaun M Eack, Ph.D.Principal Investigator

Sites

1 total
Pittsburgh, United States

Linked catalysts

1
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia — primary completion2014-05

Facts & assertions

4 sourced
Enrollment
33
Phase
PHASE1,PHASE2
Primary Completion Date
2014-05
Status
COMPLETED
relationships
The graph out of here
drug
CET/PT
drug
lead_sponsor
University of Pittsburgh Medical Center
company
collaborator
National Institute on Drug Abuse (NIDA)
company
indication
Schizoaffective Disorder
indication
Marijuana Abuse
indication
Schizophrenia
indication
investigator
Shaun M Eack, Ph.D.
person